Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice

Arthritis and Rheumatism

Volumn 62, Issue 11, 2010, Pages 3365-3373

  Rogerson, Fraser M ^a   Chung, Yuen M ^a   Deutscher, Michael E ^a   Last, Karena ^a   Fosang, Amanda J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS9 PROTEIN; AGGRECAN; AGGRECANASE 1; AGGRECANASE 2; ALANINE; ANTIBODY; CYTOKINE; EPITOPE; GLUTAMIC ACID; GLYCINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; METALLOPROTEINASE; ONCOSTATIN M; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARTILAGE CELL; ENZYME ACTIVITY; EPIPHYSIS; KNEE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION;

ADAM PROTEINS; ANIMALS; CHONDROCYTES; CYTOKINES; ENDOPEPTIDASES; MICE; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 78249235622     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27661     Document Type: Article

References (43)

1. Tortorella MD, Malfait AM,. Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. Curr Pharm Biotechnol 2008; 9: 16 - 23.
2. Stanton H, Rogerson FM, East CJ, Golub SB, Little CB, Lawlor KE, et al. ADAMTS-5 is the major aggrecanase in mouse cartilage, in vivo and in vitro. Nature 2005; 434: 648 - 51.
3. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434: 644 - 8.
4. Fosang AJ, Rogerson FM, East CJ, Stanton H,. ADAMTS-5: the story so far. Eur Cell Mater 2007; 15: 11 - 26.
5. Song RH, Tortorella MD, Malfait AM, Alston JT, Yang Z, Arner EC, et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007; 56: 575 - 85.
6. East CJ, Stanton H, Golub SB, Rogerson FM, Fosang AJ,. ADAMTS-5 deficiency blocks aggrecanase cleavage in the interglobular domain but not in the chondroitin sulfate-rich region of aggrecan. J Biol Chem 2007; 282: 8632 - 40.
7. Ilic MZ, East CJ, Rogerson FM, Fosang AJ, Handley CJ,. Distinguishing aggrecan loss from aggrecan proteolysis in ADAMTS-4 and ADAMTS-5 single and double deficient mice. J Biol Chem 2007; 282: 37420 - 8.
8. Sandy JD, Gamett D, Thompson V, Verscharen C,. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998; 335: 59 - 66.
9. Moulharat N, Lesur C, Thomas M, Rolland-Valognes G, Pastoureau P, Anract P, et al. Effects of transforming growth factor-β on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro. Osteoarthritis Cartilage 2003; 12: 296 - 305.
10. Hui W, Cawston TE, Richards CD, Rowan AD,. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL. Arthritis Res Ther 2005; 7: R57 - 64.
11. Williams RO, Feldmann M, Maini RN,. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784 - 8.
12. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB,. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797 - 809.
13. Zwerina J, Redlich K, Polzer K, Joosten L, Kroenke G, Distler J, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 2007; 104: 11742 - 7.
14. Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, et al. The modulation of matrix metalloproteinases and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002; 46: 961 - 7.
15. El Mabrouk M, Sylvester J, Zafarullah M,. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase 13 expression in human articular chondrocytes. Biochim Biophys Acta 2007; 1773: 309 - 20.
16. Plater-Zyberk C, Buckton J, Thompson S, Spaull JR, Zanders E, Papworth J, et al. Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum 2001; 44: 2697 - 702.
17. Legendre F, Bogdanowicz P, Boumediene K, Pujol JP,. Role of interleukin 6 (IL-6)/IL-6R-induced signal transducers and activators of transcription and mitogen-activated protein kinase/extracellular signal-related kinase in upregulation of matrix metalloproteinase and ADAMTS gene expression in articular chondrocytes. J Rheumatol 2005; 32: 1307 - 16.
18. Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999; 42: 1635 - 43.
19. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A 1998; 95: 8222 - 6.
20. Fosang AJ, Last K, Stanton H, Golub SB, Little CB, Brown L, et al. Neoepitope antibodies against MMP-cleaved and aggrecanase-cleaved aggrecan. Methods Mol Biol 2010; 622: 312 - 47.
21. Stewart MC, Fosang AJ, Bai Y, Osborn B, Plaas A, Sandy JD,. ADAMTS5-mediated aggrecanolysis in murine epiphyseal chondrocyte cultures. Osteoarthritis Cartilage 2006; 14: 392 - 402.
22. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM,. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15: 43 - 58.
23. Heinegard D, Sommarin Y,. Isolation and characterization of proteoglycans. Methods Enzymol 1987; 144: 319 - 372.
24. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
25. Mercuri FA, Maciewicz RA, Tart J, Last K, Fosang AJ,. Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns: evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity. J Biol Chem 2000; 275: 33038 - 45.
26. Caterson B, Christner JE, Baker JR, Lee Y, Couchman JR,. Production and characterization of monoclonal antibodies directed against connective tissue proteoglycans. Fed Proc 1985; 44: 386 - 93.
27. Durigova M, Roughley PJ, Mort JS,. Mechanism of proteoglycan aggregate degradation in cartilage stimulated with oncostatin M. Osteoarthritis Cartilage 2008; 16: 98 - 104.
28. Rogerson FM, Stanton H, East CJ, Golub SB, Tutolo L, Farmer PJ, et al. Evidence of a novel aggrecan-degrading activity in cartilage: studies of mice deficient in both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2008; 58: 1664 - 73.
29. Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T,. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 2002; 46: 2648 - 57.
30. Tortorella MD, Malfait AM, Deccico C, Arner E,. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001; 9: 539 - 52.
31. Curtis CL, Hughes CE, Flannery CR, Little CB, Harwood JL, Caterson B,. n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem 2000; 275: 721 - 4.
32. Fan Z, Bau B, Yang H, Soeder S, Aigner T,. Freshly isolated osteoarthritic chondrocytes are catabolically more active than normal chondrocytes, but less responsive to catabolic stimulation with interleukin-1β. Arthritis Rheum 2005; 52: 136 - 43.
33. Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004; 50: 131 - 41.
34. Tchetina EV, Squires G, Poole AR,. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol 2005; 32: 876 - 86.
35. Miyaki S, Nakasa T, Otsuki S, Grogan SP, Higashiyama R, Inoue A, et al. MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses. Arthritis Rheum 2009; 60: 2723 - 30.
36. Naito S, Shiomi T, Okada T, Kimura T, Chijiiwa M, Fujita Y, et al. Expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic cartilage. Pathol Int 2007; 57: 703 - 11.
37. Gendron C, Kashiwagi M, Lim NH, Enghild JJ, Thogersen IB, Hughes C, et al. Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem 2007; 282: 18294 - 306.
38. Fushimi K, Troeberg L, Nakamura H, Lim NH, Nagase H,. Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem 2008; 283: 6706 - 16.
39. Wainwright SD, Bondeson J, Hughes CE,. An alternative spliced transcript of ADAMTS-4 is present in human synovium from OA patients. Matrix Biol 2006; 25: 317 - 20.
40. Little CB, Mittaz L, Belluoccio D, Rogerson FM, Campbell IK, Meeker CT, et al. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum 2005; 52: 1461 - 72.
41. Demircan K, Hirohata S, Nishida K, Hatipoglu OF, Oohashi T, Yonezawa T, et al. ADAMTS-9 is synergistically induced by interleukin-1β and tumor necrosis factor α in OUMS-27 chondrosarcoma cells and in human chondrocytes. Arthritis Rheum 2005; 52: 1451 - 60.
42. Yaykasli KO, Oohashi T, Hirohata S, Hatipoglu OF, Inagawa K, Demircan K, et al. ADAMTS9 activation by interleukin 1β via NFATc1 in OUMS-27 chondrosarcoma cells and in human chondrocytes. Mol Cell Biochem 2009; 323: 69 - 79.
43. Yan Y, Li J, Ouyang W, Ma Q, Hu Y, Zhang D, et al. NFAT3 is specifically required for TNF-α-induced cyclooxygenase-2 (COX-2) expression and transformation of Cl41 cells. J Cell Sci 2006; 119: 2985 - 94.